Study to Assess the Safety and Pharmacokinetics of AKB-6548 in Participants With Chronic Kidney Disease (CKD), Stages 3 and 4
NCT04707573
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
22
Enrollment
INDUSTRY
Sponsor class
Conditions
Chronic Kidney Disease
Interventions
DRUG:
Vadadustat
Sponsor
Akebia Therapeutics